News and Events

SomaLogic closes $200M financing round

SomaLogic announced today that it has capped its $200 million funding round, anchored by iCarbonX with substantial investments from Nan Fung Life Sciences and Madryn Asset Management. The successful round will accelerate SomaLogic’s goal of becoming the world’s leading provider of precision digital health insights.

read more

Large-scale profiling of blood proteins identifies new markers of heart damage

A new report published online in the American Heart Association journal Circulation describes the successful measurement of changes in blood proteins at a previously unattainable scale. The results revealed a large number of proteins that increased significantly soon after a heart attack—some that are well-known markers of myocardial damage but many that are completely new. This proof-of-principle study demonstrates that comprehensive protein profiling to diagnose and treat human health and disease is on the horizon.

read more

Larry Gold named to 2017 National Academy of Inventors

The National Academy of Inventors (NAI) has named Larry Gold, the founder and chairman of the board of SomaLogic, as one of its 2017 fellows. Election to NAI Fellow status is the highest professional distinction given to academic inventors. NAI Fellows are inventors on U.S. patents and were nominated by their peers for their spirit of innovation and creation of new technologies that have significantly impacted society.

read more

Protein profiling reveals immune system dysfunction in Down syndrome

An article published online in Scientific Reports shows that Down syndrome may be a form of chronic immune disorder. In the largest and most comprehensive study of its kind to date, investigators at the Crnic Institute for Down Syndrome, the Sie Center for Down Syndrome, the University of Colorado, and Somalogic measured the levels of over 3500 proteins in the blood of Down syndrome patients and compared them to non-Down syndrome controls.

read more

Modified DNA aptamer inhibits IL-1α signaling

In an article published online in Nature Communications, scientists from SomaLogic and Yale University report that they have successfully generated a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule that binds tightly to interleukin 1 alpha (IL-1α), an essential inflammatory protein implicated in cancer and other diseases.

read more

Protein changes may signal side effects in drug trials

In an article published “early online” in the American Heart Association journal Circulation, researchers at Pfizer, the Karolinska Institute, the University of California, San Francisco and SomaLogic describe how the measurement of blood-based protein changes in response to treatment with an experimental drug candidate may improve the efficiency and safety of clinical drug development.

read more

Reynolds appointed CEO of SomaLogic

SomaLogic announced today that Board of Directors member Alister W. (Al) Reynolds has agreed to become the next company Chief Executive Officer.  He is replacing Byron Hewett, who elected to step down from the role following several years of successfully leading the company through its initial growth into a successful commercial entity.

read more

Modified DNA aptamers: Two is better than one

In a study published online in the Proceedings of the National Academy of Sciences (PNAS), SomaLogic scientists report on the generation and characterization of a new class of SOMAmer that contains two different types of modified nucleotides.

read more

SomaLogic announces that it has joined the iCarbonX Digital Life Alliance

SomaLogic announced today that it has agreed to join the “Digital Life Alliance” established by iCarbonX, the China-based company founded in 2015 to build a “Global Digital Health Ecosystem that can define each person’s ‘digital life’ based on a combination of individual’s biological, behavioral and psychological data, the Internet and artificial intelligence.”

read more

For older news and press releases, please visit our archive.

For media-related matters